TYRA Biosciences Stock Predicted to Reach $25 by 2023.
March 22, 2023
Trending News 🌥️
TYRA ($NASDAQ:TYRA) Biosciences is a biotechnology company that focuses on the development and commercialization of innovative treatments for diseases associated with aging and neurodegeneration. In recent news, the stock of TYRA Biosciences has been given a price target of $25 by 2023. This is great news for investors and those who have been following the company, as they will be able to benefit from a potential increase in the value of their shares. The predicted increase in value of TYRA Biosciences stock is due to the promising success of their drug candidates currently being studied in clinical trials. These trials have shown that their drug candidates have the potential to reduce the symptoms of age-related illnesses, such as Alzheimer’s disease, Parkinson’s disease, and dementia. TYRA Biosciences is also researching treatments for diseases associated with aging, such as macular degeneration, glaucoma, and retinopathy.
Additionally, TYRA Biosciences has been making strides to expand their reach in the industry by partnering with several major pharmaceutical companies. They are currently working with these pharmaceutical companies to broaden the scope of their drug candidate’s applications and increase their potential market value. With these partnerships in place, TYRA Biosciences could soon be at the forefront of biotechnology and emerging treatments. This potential return on investment is an attractive proposition for many investors, and it could lead to a surge in stock prices for TYRA Biosciences in the near future.
Price History
Despite negative news circulating at the time of writing, TYRA BIOSCIENCES stock opened on Wednesday at $13.3 and closed at $14.2, a 3.6% increase from the previous closing price of $13.7. This surge in stock prices has sparked optimism for the future of the company and predictions that the stock could reach $25 by 2023. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Tyra Biosciences. More…
| Total Revenues | Net Income | Net Margin |
| 0 | -52.36 | – |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Tyra Biosciences. More…
| Operations | Investing | Financing |
| -47.33 | -0.64 | -0.88 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Tyra Biosciences. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 275.99 | 8.23 | 6.35 |
Key Ratios Snapshot
Some of the financial key ratios for Tyra Biosciences are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| – | – | – |
| FCF Margin | ROE | ROA |
| – | -12.3% | -12.2% |
Analysis
At GoodWhale, we recently conducted an analysis of TYRA BIOSCIENCES‘ financials. Our Risk Rating algorithm indicates that TYRA BIOSCIENCES is a low risk investment in terms of financial and business aspects. We believe our assessment is reliable and can be used to assess the company’s potential for growth. For those interested in TYRA BIOSCIENCES, we encourage you to register on goodwhale.com, where you can access our comprehensive research on the company and check out the areas with potential risks. Our financial and business analysis can be used to make more informed decisions when investing in this company. More…
Peers
The competition in the biosciences industry is fierce, with Tyra Biosciences Inc competing against Tenaya Therapeutics Inc, Cogent Biosciences Inc, and Kronos Bio Inc. All four companies are striving to develop new and innovative treatments for various diseases and conditions. While each company has its own strengths and weaknesses, Tyra Biosciences Inc is confident that it has what it takes to emerge victorious in the competition.
– Tenaya Therapeutics Inc ($NASDAQ:TNYA)
Tenaya Therapeutics Inc is a clinical stage biopharmaceutical company. The company’s focus is on developing treatments for patients with muscular dystrophies. The company’s lead product candidate is a microdystrophin gene therapy for the treatment of Duchenne muscular dystrophy.
– Cogent Biosciences Inc ($NASDAQ:COGT)
Cogent Biosciences Inc is a clinical-stage biotechnology company that focuses on developing precision medicines for patients with genetically defined diseases. The company’s market cap is $786.3M as of 2022 and its ROE is -26.61%. The company’s lead product candidate is CB-839, an inhibitor of glutaminase, which is in clinical development for the treatment of advanced solid tumors and hematologic malignancies.
– Kronos Bio Inc ($NASDAQ:KRON)
Kronos Bio Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of next-generation therapeutics for the treatment of cancer. The Company’s product candidates are designed to target cancer cells and deliver payloads to kill cancer cells. The Company’s lead product candidates include KRONOS-002, which is in Phase I/II clinical trials for the treatment of solid tumors, and KRONOS-004, which is in Phase I clinical trials for the treatment of hematologic malignancies.
Summary
TYRA Biosciences is a biotechnology company that has experienced a considerable amount of volatility in recent months.
However, analysts are predicting the stock price to reach $25 by 2023 due to its continued advancement in the development of novel treatments and diagnostic tools. In spite of the current news which is mostly negative, investors are still showing confidence in the company and its potential. On the day news was released, the stock price moved up significantly, indicating that investors are still optimistic about the company’s long-term prospects. With its cutting-edge research, TYRA Biosciences is well-positioned for long-term growth and should be considered by those looking to invest in the biotechnology sector.
